Statin intolerance: More questions than answers

Expert Review of Clinical Pharmacology

Volumn 7, Issue 1, 2014, Pages 1-3

  Guyton, John R ^a   Campbell, Kristen B ^a   Lakey, Wanda C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

adverse effects; aging; atherosclerosis; LDL lowering; myalgia; myopathy; risk reduction; statins

Indexed keywords

ATORVASTATIN; CREATINE KINASE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; MUSCLE ENZYME; SIMVASTATIN;

CREATINE KINASE BLOOD LEVEL; DIABETOGENESIS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MORTALITY; MUSCLE BIOPSY; OXYGEN CONSUMPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME;

ATHEROSCLEROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 84893111312     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2014.857601     Document Type: Review

References (21)

1. Law M, Rudnicka AR. Statin safety: A systematic review. Am. J. Cardiol. 97(8A), C52-C60 (2006
2. Scott RS, Lintott CJ, Wilson MJ. Simvastatin and side effects. NZ Med. J. 104(924), 493-495 (1991
3. Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: An appraisal of their efficacy and safety. Eur.Heart J. 16(1), 5-13 (1995
4. Phillips PS, Haas RH, Bannykh S. et al. Statin-Associated myopathy with normal creatine kinase levels. Ann. Intern. Med. 137(7), 581-585 (2002
5. Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton Jr. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 46(10), 1206-1210 (1997
6. Sinzinger H, O'Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br. J. Clin. Pharmacol. 57(4), 525-528 (2004
7. Mikus CR, Boyle LJ, Borengasser SJ. et al. Simvastatin impairs exercise training adaptations. J. Am. Coll. Cardiol. 62(8), 709-714 (2013
8. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients -The PRIMO study. Cardiovasc. Drugs Ther. 19(6), 403-414 (2005
9. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 361(9374), 2005-2016 (2003
10. No authors listed. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 251, 351-374 (1984
11. Guyton Jr. Combination regimens with statin, niacin, and intestinally active LDL-lowering drugs: Alternatives to high-dose statin therapy? Curr. Opin. Lipidol. 21(4), 372-377 (2010
12. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: Benefit beyond cholesterol reduction? A meta-regression analysis. J. Am. Coll. Cardiol. 46(10), 1855-1862 (2005
13. Waters DD, Ho JE, Boekholdt SM. et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: Effect of baseline risk factors for diabetes. J. Am. Coll. Cardiol. 61(2), 148-152 (2013
14. Zhang H, Plutzky J, Skentzos S. et al. Discontinuation of statins in routine care settings: A cohort study. Ann. Intern. Med. 158(7), 526-534 (2013
15. Voora D, Shah SH, Spasojevic I. et al. The SLCO1B1. *5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol. 54(17), 1609-1616 (2009
16. Keating AJ, Campbell KB, Guyton Jr. Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy. Ann. Pharmacother. 47(3), 398-404 (2013
17. Pollak PT. Nondaily statin dosing: Mechanisms of a potentially important approach to dealing with statin intolerance. Can. J. Cardiol. 29(8), 895-898 (2013
18. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med. Scand. 223, 405-418 (1988
19. Whitney EJ, Krasuski RA, Personius BE. et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: Effects on progression of coronary heart disease and clinical events. Ann. Intern. Med. 142(2), 95-104 (2005
20. Jenkins DJ, Jones PJ, Lamarche B. et al. Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: A randomized controlled trial. JAMA 306(8), 831-839 (2011
21. Sullivan D, Olsson AG, Scott R. et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: The GAUSS randomized trial. JAMA 308(23), 2497-2506 (2012